Head-To-Head Review: DBV Technologies (NASDAQ:DBVT) & MeiraGTx (NASDAQ:MGTX)

MeiraGTx (NASDAQ:MGTX) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for MeiraGTx and DBV Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0	0	2	0	3.00
DBV Technologies	1	0	2	0	2.33

MeiraGTx currently has a consensus target price of $25.67, suggesting a potential upside of 377.08%. DBV Technologies has a consensus target price of $5.00, suggesting a potential upside of 646.27%. Given DBV Technologies’ higher possible upside, analysts clearly believe DBV Technologies is more favorable than MeiraGTx.

Profitability

This table compares MeiraGTx and DBV Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-599.47%	-114.33%	-42.56%
DBV Technologies	-461.32%	-46.33%	-35.32%

Institutional & Insider Ownership

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 9.7% of MeiraGTx shares are owned by company insiders. Comparatively, 0.6% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares MeiraGTx and DBV Technologies’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$14.02 million	24.68	-$84.03 million	($1.47)	-3.66
DBV Technologies	$15.73 million	8.22	-$72.73 million	($0.39)	-1.72

DBV Technologies has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MeiraGTx has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Summary

DBV Technologies beats MeiraGTx on 9 of the 13 factors compared between the two stocks.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.